SAN FRANCISCO (GenomeWeb News) – Danaher will likely use at least part of its $8 billion available for acquisitions in order to expand its life science and diagnostics portfolio, company President and CEO Larry Culp said at the 32nd Annual JP Morgan Healthcare Conference here this morning.

During the firm’s analyst day meeting last month, Culp said that the firm had at its disposal about $8 billion available to pursue merger and acquisitions and today he reiterated that figure while adding that the firm “will continue to be an active acquirer” throughout 2014 and beyond.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.